Daptomycin for the treatment of gram-positive infections after cardiac surgery

被引：0
|
作者：
Luchting, B. [1 ]
Weis, F. [1 ]
Heyn, J. [1 ]
Beiras-Fernandez, A. [2 ,3 ]
机构：
[1] Klinikum Univ Munchen, Klin Anaesthesiol, Munich, Germany
[2] Klinikum Univ Munchen, Herzchirurg Klin & Poliklin, Munich, Germany
[3] Klinikum Johann Wolfgang Goethe Univ, D-60590 Frankfurt, Germany
来源：
MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN | 2013年 / 108卷 / 01期
关键词：
Gram-positive Infections; Daptomycin; Cardiac surgery; Resistences; Efficacy; RESISTANT STAPHYLOCOCCUS-AUREUS; MAJOR HEART-SURGERY; POSTOPERATIVE MEDIASTINITIS; CLINICAL-EVIDENCE; JOINT INFECTIONS; VANCOMYCIN; THERAPY; ENDOCARDITIS; BACTEREMIA; PATIENT;
D O I：
10.1007/s00063-012-0163-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Background and method. Surgical infection remains a main cause of death after heart surgery, despite advances in pharmacological therapy. Daptomycin is a cyclic lipopeptide antibiotic, useful in gram-positive organisms resistant to standard treatment, including vancomycin. The aim of this study was to describe the use of daptomycin regarding efficacy, efficiency and safety in patients with gram-positive infections after heart surgery using a retrospective analysis on 49 adult patients. Conclusion. Daptomycin shows excellent in vitro and in vivo activity against gram-positive organisms, such as Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, especially MRSA. Daptomycin is also effective against increasing vancomycin-resistant or vancomycin-intermediate S. aureus.
引用
收藏
页码：59 / 62
页数：4
相关论文
共 50 条
  • [31] DEVELOPMENTS IN TREATMENT OF GRAM-POSITIVE INFECTIONS
    WHITBY, M
    CURRENT OPINION IN INFECTIOUS DISEASES, 1988, 1 (03) : 342 - 349
  • [32] Daptomycin therapy of Gram-positive infections (GPI) in pediatric cancer patients
    Hogan, H. L.
    Adachi, J. A.
    Coyle, E. A.
    Rolston, K. V. I.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2006, 10 : S63 - S64
  • [33] Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections
    Di Paolo, Antonello
    Tascini, Carlo
    Polillo, Marialuisa
    Gemignani, Giulia
    Nielsen, Elisabet I.
    Bocci, Guido
    Karlsson, Mats O.
    Menichetti, Francesco
    Danesi, Romano
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 (03) : 250 - 255
  • [34] Brazilian experience in EU-CORE: daptomycin registry and treatment of serious Gram-positive infections
    Timerman, Artur
    Brites, Carlos
    Bicudo, Eliana
    Grinbaum, Renato S.
    Filho, Rubens Costa
    Carrilho, Claudia D. M.
    Bichels, Andre
    Barreto, Tania
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2013, 17 (06): : 647 - 653
  • [35] Daptomycin as a promising antimicrobial agent for the treatment of serious infections caused by resistant gram-positive organisms
    Tarai, B.
    Das, P.
    Kumar, D.
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2014, 32 (03) : 353 - 354
  • [36] Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria
    Johnson, Alan
    FUTURE MICROBIOLOGY, 2006, 1 (03) : 255 - 265
  • [37] Daptomycin-containing regimens for treatment of Gram-positive endocarditis
    Russo, Alessandro
    Peghin, Maddalena
    Givone, Filippo
    Ingani, Martina
    Graziano, Elena
    Bassetti, Matteo
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 54 (04) : 423 - 434
  • [38] Daptomycin: The role of high-dose and combination therapy for Gram-positive infections
    Gould, Ian M.
    Miro, Jose M.
    Rybak, Michael J.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 (03) : 202 - 210
  • [39] TEICOPLANIN OR VANCOMYCIN IN THE TREATMENT OF GRAM-POSITIVE INFECTIONS
    MURPHY, S
    PINNEY, RJ
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1995, 20 (01) : 5 - 11
  • [40] Therapeutic options for the treatment of gram-positive infections
    De Gaudio, AR
    INFECTIONS IN THE CRITICALLY ILL: AN ONGOING CHALLENGE, 2001, : 121 - 127
12345